Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) provides biological research and development services and tools to government and commercial customers through its cell engineering and biosecurity segments. Cell engineering services help customers discover and optimize biological products and develop manufacturing… From the company’s description.
Over the twelve months to Jun 30, 2026, Ginkgo Bioworks Holdings, Inc. reported revenue of $111.86M, down 51.5% from a year earlier, and a net loss of $294.89M. Its operating margin was −259.9%, and operations used $170.24M in cash. In fiscal 2025, it reported revenue of $170.16M, down 25.1% from fiscal 2024, and a net loss of $312.76M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Ginkgo Bioworks Holdings, Inc. does
In the company’s own words
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) provides biological research and development services and tools to government and commercial customers through its cell engineering and biosecurity segments. Cell engineering services help customers discover and optimize biological products and develop manufacturing processes; Ginkgo does not make the end products. Its offerings include outsourced R&D, laboratory automation systems, biological data-generation services, AI tools and licenses to biological assets. Customers work in pharmaceuticals and biotechnology, agriculture, industrial biotechnology and government, developing products such as medicines, vaccines, crop solutions, enzymes, chemicals and food ingredients. Biosecurity services primarily serve governments, helping them monitor and analyze biological threats. The Canopy offering supports genomic data collection and biomonitoring at locations such as airports and borders, while Horizon provides digital surveillance, analytics and insights on biothreats worldwide. Ginkgo’s cell engineering platform combines laboratory automation, software, data, biological assets and scientific expertise to support customer programs.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1830214
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Ginkgo Bioworks Holdings, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Ginkgo Bioworks Holdings, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Ginkgo Bioworks Holdings, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Ginkgo Bioworks Holdings, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Ginkgo Bioworks Holdings, Inc.'s last four quarterly filings that the numbers alone won't show?”